SS-31 side effects reported in clinical trials include injection site reactions, headache, nausea, and fatigue. Learn what research says and what to watch for.
SS-31 side effects reported in human clinical trials are usually mild and include injection site reactions, headache, nausea, dizziness, and fatigue. SS-31 (elamipretide, also called MTP-131) is an investigational mitochondrial-targeted peptide that is not FDA-approved for any human use. Because the drug is still experimental, the full long-term safety picture is not yet established.
What Is SS-31 and Why People Ask About Its Side Effects
SS-31 is a synthetic tetrapeptide designed to concentrate inside mitochondria and bind to cardiolipin, a lipid in the inner mitochondrial membrane. Researchers have studied it in conditions linked to mitochondrial dysfunction, including Barth syndrome, primary mitochondrial myopathy, heart failure, and dry age-related macular degeneration.
Interest in the peptide grew after early trials hinted at possible improvements in exercise tolerance and cardiac markers. That interest is exactly why safety questions matter: whenever a peptide shows a hint of benefit, more people start searching for the ss-31 peptide side effects before deciding anything.
Reported Side Effects of SS-31 in Clinical Trials
Across published studies, most adverse events attributed to SS-31 were mild to moderate and resolved without lasting problems. The most consistent reports involve the injection itself.
- Injection site reactions: pain, redness, swelling, or a small bruise where the peptide is given.
- Headache: often described as mild and short-lived.
- Nausea: reported occasionally, usually without vomiting.
- Dizziness or lightheadedness: uncommon and typically transient.
- Fatigue: reported in some mitochondrial disease trials, though fatigue is also a symptom of the conditions being studied.
Most SS-31 side effects reported in clinical trials were mild to moderate and did not cause participants to stop treatment. Serious adverse events were uncommon, and no single serious event has been consistently linked to the peptide.
Below is a qualitative summary of how often each effect has appeared in the published literature.
| Side effect | How often reported | Typical description in trials |
|---|---|---|
| Injection site reaction | Most common | Pain, redness, swelling, or bruising at the injection site |
| Headache | Common | Mild, usually resolved within hours |
| Nausea | Occasional | Usually mild, without vomiting |
| Dizziness | Uncommon | Transient lightheadedness |
| Fatigue | Uncommon | Hard to separate from underlying disease symptoms |
| Serious adverse events | Rare | No consistent pattern tied to SS-31 |
Side Effects by Trial Population
Side effect patterns can differ depending on who is being treated. A review that summarized the side effects of ss 31 peptide across heart failure and mitochondrial disease studies described a similar overall profile, with injection site reactions and headache appearing most often.
People with Barth syndrome may be more sensitive to fluid shifts and cardiac stress, so investigators monitored those participants closely. In heart failure trials, researchers tracked blood pressure and kidney function because any vasoactive peptide can theoretically affect them.
How Often Do SS-31 Side Effects Occur?
Precise frequency estimates are difficult because SS-31 trials were small and used different doses, routes (subcutaneous injection versus intravenous infusion), and treatment durations. What is clear is that the peptide has not produced a consistent, dose-dependent pattern of severe toxicity in published human studies.
The frequency labels in the table above are qualitative categories, not exact percentages drawn from one large trial. Anyone quoting a specific percentage is likely overstating the precision of the available data.
SS-31 vs Other Peptides: Side Effect Comparison
People researching SS-31 often compare it with other injectable peptides. It helps to keep the comparisons separate, because aod 9604 benefits and side effects have nothing to do with elamipretide's mechanism. Likewise, vyleesi side effects are not relevant to SS-31 because Vyleesi is bremelanotide, an FDA-approved medication for hypoactive sexual desire disorder, not a mitochondrial peptide.
Stacking adds another layer of uncertainty. Forum reports about aod 9604 and tirzepatide together side effects cannot substitute for controlled trial data, and combining investigational peptides with approved drugs should only happen under medical supervision.
| Peptide | Common reported side effects | US approval status |
|---|---|---|
| SS-31 (elamipretide) | Injection site reactions, headache, nausea, dizziness, fatigue | Not approved |
| AOD 9604 | Injection site reactions, headache, occasional nausea | Not approved |
| Vyleesi (bremelanotide) | Nausea, flushing, headache, injection site reactions, hyperpigmentation, blood pressure increase | Approved for HSDD |
| Tirzepatide | Nausea, vomiting, diarrhea, constipation, injection site reactions | Approved for type 2 diabetes and weight management |
Safety Considerations and Who Should Be Cautious
SS-31 is not FDA-approved for human use in the United States. Anyone considering it should understand that they may be receiving a compounded or research-grade product whose purity, dose, and sterility are not guaranteed.
- People who are pregnant or breastfeeding should avoid investigational peptides unless a physician specifically recommends otherwise.
- People with heart rhythm problems, low blood pressure, or kidney disease should be cautious because SS-31's effects on those systems are not fully characterized.
- Anyone taking blood thinners or other injectable medications should discuss possible interactions with a clinician.
- Buying peptides from unregulated online vendors increases the risk of contamination and dosing errors.
Talk with a healthcare professional before using SS-31 or any research peptide. A clinician can review your medical history, current medications, and the quality of any product you are considering.
Bottom Line on SS-31 Side Effects
The side effect profile of SS-31 appears mild in the small trials completed so far, but "appears mild" is not the same as "proven safe." Long-term data are missing, and the peptide remains unapproved.
If you are weighing whether ss-31 side effects are acceptable for you, that decision belongs with a qualified healthcare provider who knows your history. For now, the most reliable information comes from peer-reviewed trials, not from marketing pages or anecdotal posts.
Frequently Asked Questions
What are the most common side effects of SS-31?
The most frequently reported SS-31 side effects in clinical trials are injection site reactions and headache. Nausea, dizziness, and fatigue have also been reported, usually as mild and short-lived events. Serious adverse events linked specifically to SS-31 have been uncommon in published studies.
Is SS-31 approved by the FDA?
No. SS-31, also known as elamipretide, has not been approved by the FDA for any human use. The manufacturer has sought approval for Barth syndrome and other mitochondrial conditions, but the agency has not granted it. Products sold online as SS-31 are therefore unapproved and unregulated.
Can SS-31 be stacked with other peptides like AOD 9604 or tirzepatide?
There is no clinical trial data on combining SS-31 with AOD 9604, tirzepatide, or other peptides. Stacking unapproved peptides with prescription drugs raises the risk of unpredictable interactions and compounding side effects. Anyone considering a combination should speak with a licensed healthcare provider first.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.